As we approach January 2025, global markets are witnessing mixed sentiment: US consumer confidence is declining and key indices such as the Nasdaq Composite are showing moderate gains against a backdrop of fluctuating economic indicators. In this environment, identifying high-growth technology stocks that can navigate these uncertainties requires a strong focus on innovation and adaptability to changing market dynamics.
| Name | Revenue growth | Earnings growth | Growth rating |
|---|---|---|---|
| Shanghai Baosight Software Ltd | 21.82% | 25.22% | ★★★★★★ |
| CD Project | 23.29% | 27.00% | ★★★★★★ |
| Ascelia Pharmacy | 76.15% | 47.16% | ★★★★★★ |
| Waystream Tenure | 22.09% | 113.25% | ★★★★★★ |
| Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
| Alnylam Pharmacy | 21.24% | 56.34% | ★★★★★★ |
| TG Therapeutics | 30.06% | 45.28% | ★★★★★★ |
| Pharmaceutical starter | 73.95% | 31.67% | ★★★★★★ |
| Elliptical laboratories | 70.09% | 111.37% | ★★★★★★ |
| Travere Therapeutics | 28.68% | 62.50% | ★★★★★★ |
Click here to see our screener’s full list of 1,262 stocks of high-growth technology and AI stocks.
Here’s a look at some of the tester’s options.
Simply Wall St Growth Rating: ★★★★★★
Overview: Bonesupport Holding AB (publ) is an orthobiology company that develops and markets injectable bioceramic bone graft substitutes in Europe, North America and other international markets, with a market capitalization of SEK 25.45 billion.
Operations: Bonesupport generates revenue primarily from its pharmaceutical segment, with SEK 814.46 million attributed to this area. The company focuses on the development and commercialization of injectable bioceramic bone graft substitutes in various regions.
BONESUPPORT Holding, amid a challenging backdrop with a 57.6% drop in profits last year, still forecasts strong future growth with expected revenue and profit increases of 33.5% and 72.2% annually, respectively . This optimism is supported by strategic investments in R&D that have always constituted a significant part of its budget, reflecting its commitment to innovation in biotechnological solutions for bone healing. Recent developments include results from the SOLARIO study that demonstrated the effectiveness of BONESUPPORT products in reducing the use of systemic antibiotics, a key advance in surgical treatments that could reshape clinical practices globally. Additionally, recent executive changes and stake acquisitions signal potential strategic changes that could influence future operations and market positioning.
